Short answer
Cytek Biosciences, Inc. (CTKB) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $48M (up 5.6% year over year) with net income of −$12M.
Q2 2026 key financials · XBRL
- Revenue
- $48M
- +5.6% YoY · +9.1% QoQ
- Net income
- −$12M
- −117.8% YoY · +35.6% QoQ
- Operating margin
- -23.7%
- Gross margin
- 58.9%
Source: XBRL data from the Cytek Biosciences, Inc. (CTKB) Q2 2026 10-Q on SEC EDGAR. USD.
Cytek Biosciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New product-development risk triggered by June 2026 Cytek Borealis early-access launch
- Most materially updated trade risk: U.S. tariffs on Singapore and China imports increased from 10% to 12.5%
- Regulatory compliance exposure: foreign distributor activity may implicate FCPA books-and-records and anti-bribery provisions
- Near-term operational risk: sole-source lasers and semiconductors require 12–24 months or longer for replacement qualification
- Financial risk: instrument sales cycles extending up to six months or longer drive quarterly revenue volatility
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cytek Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.